Literature DB >> 19168871

Molecular mechanisms of ovarian hyperstimulation syndrome: paracrine reduction of endothelial claudin 5 by hCG in vitro is associated with increased endothelial permeability.

M Rodewald1, D Herr, W C Duncan, H M Fraser, G Hack, R Konrad, F Gagsteiger, R Kreienberg, C Wulff.   

Abstract

BACKGROUND: Ovarian hyperstimulation syndrome (OHSS) is a potentially life-threatening complication of ovarian stimulation associated with severe vascular hyperpermeability. Primary co-cultures of human luteinized granulosa cells (LGCs) and human umbilical vein endothelial cells (HUVECs) were used as a model of steroidgenic/endothelial cell interaction in OHSS.
METHODS: hCG and the vascular endothelial growth factor (VEGF) inhibitor, Flt-1Fc, were added to co-cultures of LGCs and HUVECs separated by a micropore membrane. Endothelial permeability to labeled bovine serum albumin was measured and the expression of the endothelial cell-specific adhesion protein claudin 5 was investigated using immunocytochemistry and western blotting.
RESULTS: The addition of hCG increased HUVEC permeability in the presence of LGCs (P < 0.05). hCG increased VEGF concentrations in both chambers of the co-culture system (P < 0.05). The increased permeability in the presence of LGCs and hCG was inhibited when VEGF was blocked by Flt-1Fc (P < 0.05). Endothelial membrane claudin 5 protein was reduced in the presence of hCG and LGCs, as measured by immunocytochemistry (P < 0.05) and western blotting (P < 0.05) and this reduction was inhibited by Flt-1Fc. hCG had no direct effects on endothelial cell claudin 5.
CONCLUSIONS: For OHSS, this novel paradigm suggests that hCG can increase endothelial permeability by up-regulating VEGF in LGCs which causes reduction in endothelial claudin 5 expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168871     DOI: 10.1093/humrep/den479

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  Slit2/Robo4 Signaling: Potential Role of a VEGF-Antagonist Pathway to Regulate Luteal Permeability.

Authors:  I Bekes; V Haunerdinger; R Sauter; I Holzheu; W Janni; A Wöckel; C Wulff
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-01       Impact factor: 2.915

2.  Regulation of Endothelial Permeability in the Corpus Luteum: A Review of the Literature.

Authors:  D Herr; I Bekes; C Wulff
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-11       Impact factor: 2.915

Review 3.  Ovarian hyperstimulation syndrome: pathophysiology and prevention.

Authors:  Carolina O Nastri; Rui A Ferriani; Isa A Rocha; Wellington P Martins
Journal:  J Assist Reprod Genet       Date:  2010-02-06       Impact factor: 3.412

4.  Inhibition of delta-like ligand 4 induces luteal hypervascularization followed by functional and structural luteolysis in the primate ovary.

Authors:  Hamish M Fraser; Julie M Hastings; Deborah Allan; Keith D Morris; John S Rudge; Stanley J Wiegand
Journal:  Endocrinology       Date:  2012-02-14       Impact factor: 4.736

5.  Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?

Authors:  Inga Bekes; Thomas W P Friedl; Tanja Köhler; Volker Möbus; Wolfgang Janni; Achim Wöckel; Christine Wulff
Journal:  Mol Cancer       Date:  2016-02-12       Impact factor: 27.401

6.  Intravenous neutralization of vascular endothelial growth factor reduces vascular function/permeability of the ovary and prevents development of OHSS-like symptoms in rhesus monkeys.

Authors:  C V Bishop; D M Lee; O D Slayden; X Li
Journal:  J Ovarian Res       Date:  2017-07-06       Impact factor: 4.234

Review 7.  Claudins overexpression in ovarian cancer: potential targets for Clostridium Perfringens Enterotoxin (CPE) based diagnosis and therapy.

Authors:  Diana P English; Alessandro D Santin
Journal:  Int J Mol Sci       Date:  2013-05-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.